<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01028794</url>
  </required_header>
  <id_info>
    <org_study_id>UMIN000001133</org_study_id>
    <secondary_id>UMIN000001133</secondary_id>
    <nct_id>NCT01028794</nct_id>
  </id_info>
  <brief_title>Autologous Bone Marrow Mononuclear Cell Transplantation for Stroke Patients</brief_title>
  <official_title>Phase 1/2A Study of Intravenous Autologous Bone Marrow Mononuclear Cell Transplantation for Patients After Cerebral Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cerebral and Cardiovascular Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Biomedical Research and Innovation, Kobe, Hyogo, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cerebral and Cardiovascular Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether autologous bone marrow mononuclear cells
      transplantation after stroke is safe and/or effective to improve neurological outcome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of NIHSS（National Institute of Health Stroke Scale）</measure>
    <time_frame>30 days after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of change for the worse in NIHSS</measure>
    <time_frame>30 days aftrer treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean level of mRS (modified Rankin Scale)</measure>
    <time_frame>30 days after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of death</measure>
    <time_frame>day 30 after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Cerebral Embolism</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>autologous bone marrow mononuclear cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On day 7-10 after stroke, patient has 25ml of bone marrow cells aspiration. Mononuclear cells are purified by Ficoll and administrated intravenously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>autologous bone marrow mononuclear cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On day 7-10 after stroke, patient has 50ml of bone marrow cells aspiration. Mononuclear cells are purified by Ficoll and administrated intravenously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous bone marrow mononuclear cells</intervention_name>
    <description>intravenous administration of autologous bone marrow derived mononuclear cells obtained from 25ml of bone marrow on day 7-10 after stroke (only once in that period)</description>
    <arm_group_label>autologous bone marrow mononuclear cell</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous bone marrow mononuclear cells</intervention_name>
    <description>intravenous administration of autologous bone marrow derived mononuclear cells obtained from 50ml of bone marrow on day 7-10 after stroke (only once in that period)</description>
    <arm_group_label>autologous bone marrow mononuclear cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with cerebral embolism.

          -  NIHSS score is more than (or equal to) 10.

          -  On day 7 after onset of stroke, the improvement of NIHSS is less than (or equal to) 5,
             compared with the level at administration.

          -  Bone marrow aspiration can be done in 10 days after onset of stroke

        Exclusion Criteria:

          -  Patient with cerebral hemorrhage or symptomatic hemorrhagic infarction.

          -  Patient who expects brain surgery.

          -  Patient with acute myocardial infarction.

          -  Patient with coagulation disorder.

          -  Number of Platelet &lt; 100000/mm3

          -  Serum creatinine level &gt;2.0mg/dl

          -  Patient with malignancy.

          -  Patient with uncontrolled proliferative diabetic retinopathy.

          -  Patient suspected infective endocarditis.

          -  HBV, HCV, HIV or HTLV positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Akihiko Taguchi, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cerebrovascular Disease, National Cardiovascular Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cerebrovascular Disease, National Cardiovascular Center</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-8565</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Taguchi A, Soma T, Tanaka H, Kanda T, Nishimura H, Yoshikawa H, Tsukamoto Y, Iso H, Fujimori Y, Stern DM, Naritomi H, Matsuyama T. Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest. 2004 Aug;114(3):330-8.</citation>
    <PMID>15286799</PMID>
  </reference>
  <reference>
    <citation>Taguchi A, Ohtani M, Soma T, Watanabe M, Kinosita N. Therapeutic angiogenesis by autologous bone-marrow transplantation in a general hospital setting. Eur J Vasc Endovasc Surg. 2003 Mar;25(3):276-8.</citation>
    <PMID>12623341</PMID>
  </reference>
  <reference>
    <citation>Taguchi A, Matsuyama T, Moriwaki H, Hayashi T, Hayashida K, Nagatsuka K, Todo K, Mori K, Stern DM, Soma T, Naritomi H. Circulating CD34-positive cells provide an index of cerebrovascular function. Circulation. 2004 Jun 22;109(24):2972-5. Epub 2004 Jun 7.</citation>
    <PMID>15184275</PMID>
  </reference>
  <reference>
    <citation>Taguchi A, Wen Z, Myojin K, Yoshihara T, Nakagomi T, Nakayama D, Tanaka H, Soma T, Stern DM, Naritomi H, Matsuyama T. Granulocyte colony-stimulating factor has a negative effect on stroke outcome in a murine model. Eur J Neurosci. 2007 Jul;26(1):126-33.</citation>
    <PMID>17614944</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2009</study_first_submitted>
  <study_first_submitted_qc>December 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2009</study_first_posted>
  <last_update_submitted>July 4, 2013</last_update_submitted>
  <last_update_submitted_qc>July 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cerebral and Cardiovascular Center</investigator_affiliation>
    <investigator_full_name>Akihiko Taguchi</investigator_full_name>
    <investigator_title>guest investigator</investigator_title>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>bone marrow</keyword>
  <keyword>mononuclear cell</keyword>
  <keyword>angiogenesis</keyword>
  <keyword>neurogenesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Intracranial Embolism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

